| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials | Sarah de Crescenzo | 08/11/20 | National |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs | Frank Vinluan | 12/10/19 | New York |
| PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome | Frank Vinluan | 06/26/19 | Boulder/Denver |
| With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease | Frank Vinluan | 06/10/19 | Boston |
| With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes | Frank Vinluan | 05/30/19 | San Francisco |
| Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More | Frank Vinluan | 02/22/19 | National |
| Amgen Picks Provention to Continue Development of Celiac Disease Drug | Frank Vinluan | 11/05/18 | New York |
| Microbiome Startup uBiome Expands into Drug Research with $83M | Frank Vinluan | 09/21/18 | San Francisco |
| Dutch Biotech Raises $19M to Develop Psoriasis Drug Near San Diego | Bruce V. Bigelow | 03/14/18 | San Diego |
| Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders | Frank Vinluan | 01/18/18 | Boston |
| Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug | Frank Vinluan | 05/30/17 | San Francisco |
| Bio Roundup: Gottlieb Talks Vax, Acorda’s Axe, Adams, 23andMe & More | Alex Lash | 04/07/17 | National |
| Early Data for Celgene’s Oral Crohn’s Drug Gets Mixed Reaction | Ben Fidler | 10/17/16 | New York |
| Sofinnova, Atlas Put $35M Into Delinia to Tackle Autoimmune Diseases | Ben Fidler | 09/14/16 | Boston |
| Celgene Touts Data From Early Study of Oral GI Drug | Ben Fidler | 09/12/16 | Boston |
| Harvard’s Springer Gets $51.5M From Pharmas, Others, For Latest Startup | Ben Fidler | 06/30/16 | Boston |
| Atlas, Novartis Put $27M Into IFM to Battle Cancer, Autoimmune Diseases | Ben Fidler | 06/22/16 | Boston |
| Vedanta Nabs $50M To Expand Microbiome Into Immune-Boosting Therapies | Ben Fidler | 06/06/16 | Boston |
| NY Bio Startup Syntimmune Gets $10M From Baxalta, Apple Tree | Ben Fidler | 03/22/16 | New York |
| Synlogic Nabs $40M, Prepares To Put Modified Microbes Into Patients | Ben Fidler | 02/17/16 | Boston |
| In New York and Montreal, Versant Seeds Two New Biotech Startups | Ben Fidler | 12/10/15 | New York |
| Biogen Pays $60M to Take on Celgene With a Rival Autoimmune Drug | Ben Fidler | 09/09/15 | Boston |
| East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More | Ben Fidler | 06/12/15 | Boston |
| West Coast Biotech Roundup: Illumina, Veracyte, Otonomy, Kite & More | Alex Lash | 05/22/15 | San Diego |
| After Shift to Duchenne and Cholesterol Drugs, Catabasis Files For IPO | Ben Fidler | 05/14/15 | Boston |
| With Vedanta Deal, J&J Marks Big-Pharma Milestone in the Microbiome | Alex Lash | 01/13/15 | Boston |
| West Coast Biotech Roundup: CareFusion, Sunesis, Second Genome, Etc. | Alex Lash | 10/09/14 | San Francisco |
